*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung
About email@example.comThis author has not yet filled in any details.
So far firstname.lastname@example.org has created 10 blog entries.
*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to
*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had
*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer.
*December 10, 2018, University of Texas M. D. Anderson Cancer Center* Researchers at The University of Texas MD Anderson Cancer Center
June 12 2018. A first of its kind treatment vaccine has moved into a phase I clinical trial for patients
Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR email@example.comT12:55:52+00:00
*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains
*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with
By Donna Fernandez · November 9, 2018. I generally begin November by listing, day by day, that for which I am grateful. Some days, the